Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Biliary Tract Neoplasms 2Advanced or Metastatic Solid Tumors 2Thymoma 1Solid Tumor 1Sarcoma 1Piebaldism 1Gastrointestinal Stromal Tumors 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1

Interventions

Bevacizumab 35durvalumab 23atezolizumab 22Nivolumab 20lenvatinib 19tremelimumab 16Specimen Handling 14Magnetic Resonance Spectroscopy 12sintilimab 11pembrolizumab 9Ipilimumab 9tislelizumab 7Sorafenib 7cabozantinib 5X-Rays 5Immunoglobulin G 5Disulfides 5Cyclophosphamide 5regorafenib 4Radiotherapy 4Radiosurgery 4Radiation 4Oxaliplatin 4Immunotherapy 4Ethiodized Oil 4fludarabine 3donafenib 3Surgical Procedures, Operative 3Folfox protocol 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × envafolimab × 90 days × Clear all
NCT05024214 2026-03-25

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

3D Medicines

Phase 1/2 Recruiting
170 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡